共 50 条
- [21] Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)BLOOD, 2020, 136Thomas, Sheeba K.Shah, Jatin J.Morin, ArmandoMorphey, Ashley N.Lee, Hans C.Manasanch, Elisabet E.Patel, Krina K.Kaufman, Gregory P.Iyer, Swami P.Feng, LeiAmini, BehrangQazilbash, Muzaffar H.Bashir, QaiserSaini, NeerajSrour, Samer A.Johnson, Ralph J.Crumpton, Brandon N.Stafford, Mildred D.Weber, Donna M.Orlowski, Robert Z.
- [22] Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBLOOD, 2023, 142Kastritis, EfstathiosPalladini, GiovanniDimopoulos, Meletios AthanasiosJaccard, ArnaudMerlini, GiampaoloTheodorakakou, FoteiniFotiou, DespinaMinnema, Monique C.Wechalekar, Ashutosh D.Papachristou, ElenaPsarros, GiorgosSonneveld, PieterSchonland, Stefan
- [23] Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the European Myeloma NetworkAMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S72 - S73Kastritis, EfstathiosPalladini, GiovanniDimopoulos, Meletios A.Jaccard, ArnaudMerlini, GiampaoloTheodorakakou, FoteiniFotiou, DespinaMinnema, Monique C.Wechalekar, AshutoshNinos, IoannisPsarros, GiorgosSonneveld, PieterSchoenland, Stefan
- [24] Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBLOOD, 2022, 140 : 7294 - 7296Kastritis, EfstathiosPalladini, GiovanniDimopoulos, Meletios-AthanasiosJaccard, ArnaudMerlini, GiampaoloTheodorakakou, FoteiniFotiou, DespinaMinnema, Monique C.Wechalekar, Ashutosh D.Varghese, SreejaManousou, KyriakiSonneveld, PieterSchoenland, Stefan
- [25] Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma PatientsBLOOD, 2021, 138Garderet, LaurentKuhnowski, FrederiqueBerge, BenoitRoussel, MurielleEscoffre-Barbe, MartineLafon, IngridFacon, ThierryLeleu, XavierKarlin, LionelPerrot, AuroreMoreau, PhilippeMarit, GeraldStoppa, Anne-MarieRoyer, BrunoChaleteix, CarineTiab, MouradAraujo, CarlaLenain, PascalMarco, MargaretVoog, Eric G.Benboubker, LotfiAllangba, Olivier ThierryJourdan, EricOrsini-Piocelle, FrederiqueBrechignac, SabineEveillard, Jean-RichardBelhadj, KarimWetterwald, MarcPegourie, BrigitteJaccard, ArnaudEisenmann, Jean ClaudeGlaisner, SylvieMohty, MohamadHulin, CyrilleLoiseau, Herve AvetMathiot, ClaireAttal, Michel
- [26] A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple MyelomaBLOOD, 2022, 140 : 4405 - 4406Terpos, EvangelosGavriatopoulou, MariaNtanasis-Stathopoulos, IoannisMalandrakis, PanagiotisFotiou, DespinaKanellias, NikolaosMigkou, MagdaliniTheodorakakou, FoteiniSpiliopoulou, VasilikiSyrigou, RodanthiPapaiakovou, Evangelos EleutherakisGkolfinopoulos, StavrosManousou, KyriakiKastritis, EfstathiosDimopoulos, Meletios A.
- [27] Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyLANCET ONCOLOGY, 2020, 21 (02): : 207 - 221Lonial, SagarLee, Hans C.Badros, AshrafTrudel, SuzanneNooka, Ajay K.Chari, AjaiAbdallah, Al-OlaCallander, NatalieLendvai, NikolettaSborov, DouglasSuvannasankha, AttayaWeisel, KatjaKarlin, LionelLibby, EdwardArnulf, BertrandFacon, ThierryHulin, CyrilleKortum, K. MartinRodriguez-Otero, PaulaUsmani, Saad Z.Hari, ParameswaranBaz, RachidHang QuachMoreau, PhilippeVoorhees, Peter M.Gupta, IraHoos, AxelZhi, EricBaron, JanuaryPiontek, TrishaLewis, EricJewell, Roxanne C.Dettman, Elisha J.Popat, RakeshEsposti, Simona DegliOpalinska, JoannaRichardson, PaulCohen, Adam D.
- [28] Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S170 - S171Shafi-Harji, SeemaNugent, CourtneyFerron-Brady, GeraldineDelimpasi, SosanaDimopoulos, MeletiosChen, YunxinChng, Wee JooLee, Jae HoonAilawadhi, SikanderGowin, KrisstinaArning, MichaelStruemper, Herbert
- [29] Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II StudyCLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2014, 8 : 101 - 105Byrne, MichaelSalmasinia, DonyaLeather, HelenCogle, Christopher R.Davis, AmyHsu, Jack W.Wiggins, LauraChang, Myron N.An, QiWingard, John R.Moreb, Jan S.
- [30] Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplantJOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1613 - 1616Shockley, AbigailDavis, James A.Gaffney, Kelly J.Smith, DeidraWeeda, ErinHashmi, Hamza